Podcasts about ldl c

This video explores the significant potential of bergamot, particularly its Bergamot Polyphenolic Fraction (BPF), in managing cholesterol levels, based on a review in Nutrients. Bergamot primarily lowers cholesterol by inhibiting HMG-CoA reductase, the same enzyme targeted by statins, with compounds like brutieridin and melitidin playing a key role ; in vitro studies have shown up to a 30-40% reduction in cholesterol synthesis in liver cells. Clinical trials demonstrate notable LDL-C reductions, for example, 500 mg/day of BPF decreased LDL-C by 24.1% in 30 days , while 1000 mg/day lowered LDL-C by 40.8%. Doses up to 1300 mg/day have resulted in LDL-C reductions of 37.7% over 120 days in patients with metabolic syndrome.Regarding safety, bergamot has generally been well-tolerated in human trials lasting up to 120 days, with no significant adverse effects reported. Animal studies also indicate a good safety profile, with doses up to 150 mg/kg/day of BPF showing no liver, kidney, or blood toxicity. Even in statin-intolerant patients, 1500 mg/day of bergamot extract showed favorable results without adverse effects in one study. However, it's important to note that data on long-term safety and use at higher doses are still limited. Caution is advised for individuals on multiple medications due to the potential for drug-nutraceutical interactions, which are not yet fully understood.Disclaimers:"This information is for educational purposes only and should not be interpreted as medical advice.""The review discusses findings from preclinical studies and clinical trials. While short-term human studies (up to 120 days) suggest bergamot is generally well-tolerated , comprehensive long-term safety data, especially at higher doses, is still emerging. The effects of bergamot can vary based on the individual, the formulation, and dosage.""Always consult with a qualified healthcare professional before making any changes to your diet, supplement regimen, or treatment plan, particularly if you have a medical condition, are taking medications (especially for cholesterol or other cardiovascular issues), or are considering bergamot supplementation. Discuss potential interactions if you are on polypharmacy.""This channel does not provide medical advice."#BergamotCholesterol #NutraceuticalSafety #LipidManagement #HeartHealthSupplements #BergamotCarpenito M, Coletti F, Muscoli S, Guarino L, Di Cristo A, Cammalleri V, Mega S, Emerenziani S, Cicala M, Fanali C, et al. Unveiling the Power of Bergamot: Beyond Lipid-Lowering Effects. Nutrients. 2025; 17(11):1871. https://doi.org/10.3390/nu17111871Alchepharma,Ralph Turchiano,Bergamot cholesterol reduction,bergamot safety profile,bergamot side effects,bergamot HMG-CoA reductase,bergamot triglycerides,bergamot clinical trials cholesterol,safe cholesterol supplements,natural cholesterol lowering,bergamot long-term use,bergamot dosage for cholesterol,bergamot vascular benefits,bergamot antioxidant heart,bergamot and statins,small dense LDL reduction,dyslipidemia nutraceuticals,bergamot mechanisms of action

Dans cet épisode en partenariat avec Shopify, Laurent Kretz reçoit Olivier de la Clergerie, Directeur Général et cofondateur du Groupe LDLC, pour un épisode enregistré en live à Lyon au sein du prestigieux Grand Hôtel-Dieu. Ensemble, ils explorent la trajectoire impressionnante d'un des pionniers du e-commerce français, qui a su évoluer d'un distributeur spécialiste à une marque grand public tout en gardant une exigence de service premium.Dans cet échange, on découvre que rendre son expertise accessible, miser sur le branding sportif et culturel, réussir l'intégration humaine lors des croissances externes, et maintenir un service client d'excellence sont des leviers essentiels pour bâtir une marque e-commerce forte et durable.Dans cet épisode, Laurent et Olivier reviennent sur :00:00:00 – Introduction et parcours d'Olivier de la Clergerie00:07:30 – Le pari du naming sportif : LDLC Arena et ASVEL00:12:10 – Diversification et gestion multi-marques00:22:30 – Développement du B2B et adaptation au marché00:27:50 – Les défis de la croissance externe et l'importance de l'humain00:38:20 – L'impact du digital sur la relation client00:46:30 – Vision d'avenir et conseils aux entrepreneurs00:54:00 – Les enjeux de la logistique et de l'expérience clientEt quelques dernières infos à vous partager : Suivez Le Panier sur Instagram lepanier.podcast !Inscrivez- vous à la newsletter sur lepanier.io pour cartonner en e-comm ! Écoutez les épisodes sur Apple Podcasts, Spotify ou encore Podcast AddictLe Panier est un podcast produit par Cosa, du label Orso Media.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In this Healthed lecture, Prof Andrew Sindone will discuss the ever lower targets for LDL-C particularly in secondary prevention as well as presenting data that shows even high risk populations are failing to meet these targets. He will also discuss the latest available therapy for persistently elevated LDL-C levels that has proven benefits in terms of effectiveness, safety, accessibility and compliance.See omnystudio.com/listener for privacy information.

Listener feedback, CRT vs CSP, important clues on the ECG, beta-blocker interruption after myocardial infarction, novel approaches to LDL-C lowering, and ICD decisions in cardiac sarcoidosis are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback II CRT vs CSP – CONSYST-CRT • Trial JACC EP https://doi.org/10.1016/j.jacep.2025.03.024 III The Important QRS • Kewcharoen et al https://www.ahajournals.org/doi/10.1161/CIRCEP.125.013809 IV ABYSS Trial of BB Interruption after MI Continues to be Mis-interpreted • ABYSS Main https://www.nejm.org/doi/full/10.1056/NEJMoa2404204 • ABYSS substudy https://doi.org/10.1093/eurheartj/ehaf170 • REDUCE AMI https://www.nejm.org/doi/full/10.1056/NEJMoa2401479 V Oral PCSK9i and the PURSUIT Trial • Koren et al https://www.jacc.org/doi/10.1016/j.jacc.2025.03.499 • Editorial https://doi.org/10.1016/j.jacc.2025.03.518 • Is Lifelong LDL-C Lowering Within Reach? The heart-1 Gene-Editing Trial https://www.medscape.com/viewarticle/998162 • Heart-1 Gene Therapy Trial Pauses Enrollment https://www.medscape.com/viewarticle/998162 • EHJ coverage VERVE https://academic.oup.com/ehjcvp/article/10/2/87/7455877 VI Cardiac Sarcoidosis and Risk of VT • EHJ paper Mathijssen et al https://doi.org/10.1093/eurheartj/ehaf338 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Welcome back to our weekend Cabral HouseCall shows!   This is where we answer our community's wellness, weight loss, and anti-aging questions to help people get back on track!   Check out today's questions:     Kellie: Hi Dr. Cabral! I have been with your program for almost 6 months now. I have completed the Vit-Tox tests and have gone through the FM Detox twice and now going through the CBO Protocol. I just turned 38 years old and I feel like my joints are of an 80 year old. I have played soccer since age 5 and still play on a competitive coed league to this day. I have played many other team/contact sports in the past. I have had past ankle, knee, and hip injuries due to sports and I do see possible knee and hip replacements in my future. When I do my daily workouts or go up/down stairs my ankles, knees, hips, and back crack or pop so easily and so much. I don't see glucosamine chondroitin as a supplement in your shop. Are there any suggestions you may have to keep my joints healthier? Thank you!!              Jon: Hey Dr Cabral, looking for advice and i feel like there's a population that struggles with this same topic. My Dr is recommending a statin due to my high LDL-C of 230. My LDL has gone up after cleaning up my diet in the last 7 months however ALL of my markers tested for have improved. Triglycerides have gone from over 200 to 100, HDL is up to 60, VLDL has dropped from 30 to 15, A1C is 5.2, blood pressure is normal for the first time ever, and so onr. My personal opinion is that i'm healthier than ever and i can't imagine having to go on what seems like a lifetime drug due to one marker being off and i don't buy the story that LDL alone is a concern for me. Curious on your opinion here and if you think i have something to worry about. Thanks!!                                                                                                                            Annette: I've been diagnosed with nephrocalcinosis by conventional doctors who say the cause is genetic. I have adjusted my diet to low sodium, low oxalate foods. The doctors say my next step is to try to get on the kidney transplant list before I need dialysis. I take potassium citrate and a calcitriol. Is there anything I can do to improve my kidney function?                                                                                                  Summer: Hi Dr. Cabral! I heard you say that it's best to replace aluminum cookware, but not necessary, and instead to use parchment paper as a barrier. Doesn't the aluminum off gas when heated? How does parchment paper prevent the aluminum from getting into the food? Thanks! By the way, to all my fellow listeners: please contact your state representatives and let them know you do not consent to geo-engineering in your skies. Several states have now banned it. We could all live healthier lives if we could work toward eliminating toxins and heavy metals including aluminum that are regularly being sprayed into our air.                                                                                                                                                Ann: Thank you Dr Cabral- you are changing SO many lives - thank you for all of your wisdom and teachings:) I have a question about Magnesium. My cortisol was high at my last lab test, and I took Full Spectrum magnesium for 12 weeks, and now I take Cal Mag daily. I also understand that I can take Calming Magnesium and CBD at night to help with sleep.I don't want to take too much for too long for my body, but I still think I need the help for my cortisol levels/ sleep. What combination of the above do you recommend? Is there a length of time that is too long to be on Full Spectrum Magnesium? PS. I do the 3-2-1 protocol, take Adrenal Soothe and will be repeating my big 5 this fall. Thank you again!           Thank you for tuning into today's Cabral HouseCall and be sure to check back tomorrow where we answer more of our community's questions!      - - - Show Notes and Resources: StephenCabral.com/3396 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

DisclaimerThis podcast represents the opinions of Your Life, Reset and guests to the show. The content here should not be taken as, or considered a substitute for, medical advice, diagnosis and/or treatment, for either yourself or others, including but not limited to individuals you may be treating. The content here is for informational purposes only, and because each person is unique, please consult your medical provider for any medical questions or if you have, or suspect you have, a medical problem. In no way does listening, reading, emailing or interacting on social media with our content establish a doctor-patient relationship.Views and opinions expressed in the podcast are our own and do not necessarily represent that of our places of work. While we make every effort to ensure that the information we are sharing is accurate, we welcome any comments, suggestions, or correction of errors.Privacy is of the utmost importance to us. Where appropriate, the people, places, and scenarios mentioned in the podcast may be changed to protect patient confidentiality.This podcast should not be used in any legal capacity whatsoever, including but not limited to establishing “standard of care” in a legal sense or as a basis for expert witness testimony. No guarantee is given regarding the results or accuracy of any statements or opinions made on the podcast.This entire disclaimer also applies to any guests or contributors to the podcast. Under no circumstances shall any guests or contributors to the podcast, or any employees, associates, or affiliates of Virta Health be responsible for damages arising from use of the podcast.If you find any errors in any of the content, please send a message through our form here: https://virtahealth.zendesk.com/hc/en-us/requests/newThis podcast is owned by Virta Health. The contents of Your Life, Reset and show notes are all copyrighted Virta Health. All posts, podcasts, and show notes that are distributed to the public for free can be re-distributed via hard copy or electronic copy for free ONLY if Virta Health is included as the acknowledged author within the actual media that is re-distributed.Your Life, Rest: privacy policy (link) and terms and conditions (link).

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for April 28-May 4, 2025: Obicetrapib Achieves Robust LDL-C Reductions in Phase 3 ASCVD Trials Obicetrapib significantly reduced LDL-C as monotherapy and in combination with ezetimibe in ASCVD patients inadequately controlled by statins, according to Phase 3 data presented at EAS 2025. MAR001 Cuts Remnant Cholesterol, Triglycerides by 50% in Phase 2a Trial MAR001, a novel ANGPTL4-targeting monoclonal antibody, reduced remnant cholesterol and triglycerides by over 50% in high-risk patients, suggesting a promising new cardiovascular intervention strategy. Oral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial Zervimesine (CT1812) slowed lesion progression in geographic atrophy secondary to AMD in Phase 2 MAGNIFY trial results, offering a potential oral treatment option. UBX1325 Matches Aflibercept in Vision Gains for DME at 36 Weeks UBX1325 demonstrated noninferiority to aflibercept in visual acuity gains in patients with diabetic macular edema over 36 weeks in the Phase 2b ASPIRE study. Roflumilast Foam 0.3% for Scalp, Body Psoriasis Effective, Safe for Patients Roflumilast foam 0.3% achieved significant efficacy and rapid symptom control in scalp and body psoriasis, with an FDA decision expected by late May 2025.

Save 20% on all Nuzest Products WORLDWIDE with the code MIKKIPEDIA at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comThis week on the podcast, Mikki speaks to Dr. Matt Budoff – a world-renowned cardiologist and researcher who has spent decades at the forefront of cardiovascular imaging and prevention. Known for his pioneering work in coronary artery calcium (CAC) scoring and computed tomography angiography (CCTA), Dr. Budoff has helped transform how we detect and assess heart disease risk.In this conversation, we explore what first sparked his interest in cardiovascular imaging and how his views on lipids, plaque, and heart disease risk have evolved over time. We dig into his recent research on lifestyle interventions—particularly low-carbohydrate and ketogenic diets—and how they affect LDL cholesterol, atherosclerosis, and overall coronary health.We also discuss the implications of his KETO study, which found no direct correlation between elevated LDL-C and plaque burden in lean, metabolically healthy individuals following a ketogenic diet.Dr. Matthew J. Budoff is a distinguished cardiologist and professor of medicine at the David Geffen School of Medicine at UCLA. He holds the Endowed Chair of Preventive Cardiology at Harbor-UCLA Medical Center and serves as the Program Director and Director of Cardiac CT in the Division of Cardiology Renowned for his pioneering work in non-invasive cardiovascular imaging, Dr. Budoff has significantly advanced the use of coronary artery calcium (CAC) scoring and computed tomography angiography (CCTA) to detect and monitor coronary artery disease. His research focuses on early detection methods for cardiac disease, aiming to identify high-risk patients and implement preventive strategies Dr. Budoff has authored or co-authored over 50 books and book chapters and more than 2,000 articles and abstracts. His contributions have been recognised with numerous awards, including the Gold Medal Award from the Society of Cardiovascular Computed Tomography and designation as a Master of the Society Matt Budoff https://profiles.ucla.edu/matthew.budoffLMHR https://www.jacc.org/doi/10.1016/j.jacadv.2024.101109  Curranz Supplement: Use code MIKKIPEDIA to get 20% off your first order - go to www.curranz.co.nz  or www.curranz.co.uk to order yours Contact Mikki:https://mikkiwilliden.com/https://www.facebook.com/mikkiwillidennutritionhttps://www.instagram.com/mikkiwilliden/https://linktr.ee/mikkiwilliden

What if everything we thought we knew about cholesterol and heart disease risk… doesn't apply to everyone?In this episode, world-renowned cardiologist Dr. Matthew Budoff unpacks the results of a landmark one-year study tracking 100 lean, metabolically healthy individuals on a ketogenic diet with extremely elevated LDL levels.Dr. Budoff is the Program Director, Director of Cardiac CT, and the endowed chair of preventive cardiology at The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.In this interview, Dr. Scher and Dr. Budoff further break down the results of his new publication, which used advanced imaging to demonstrate that LDL cholesterol and ApoB levels are not associated with plaque progression in Lean-Mass Hyper Responders following a ketogenic diet.

What if everything you thought you knew about cholesterol, fat, and metabolic health was up for debate? As someone interested in nutrition research, I'm always up for exploring differing points of view especially when they come from a rigorous scientific background and can speak to the evidence base. So in this episode, I sit down with Dr Nick Norwitz PhD, to challenge some of my long held positions in nutrition science and break down keto.He's a researcher and expert in ketogenic diets, lipid metabolism, and metabolic health as well as a current medical student at Harvard Medical school.We discuss:

Is LDL cholesterol the best way to measure and predict heart disease?New research suggests no!Dave Feldman is an engineer turned citizen scientist who has devoted his life to understanding a phenomenon that some individuals around the world are experiencing: a robust increase in LDL cholesterol while on a ketogenic diet.Dave's past research has identified a unique phenotype dubbed Lean Mass Hyper-Responders (LMHRs). LMHRs respond to ketogenic therapy with a metabolic profile that includes elevated LDL-C and ApoB levels with otherwise healthy metabolic markers, including low triglycerides, high HDL, low blood pressure, low insulin resistance, and low BMI.In Dave's most recent publication, what most doctors would consider dangerously high LDL levels in LMHRs did not correlate with an increased risk of heart disease.In this video, Dr. Bret Scher sits down with Dave Feldman to discuss this groundbreaking study and its implications for ketogenic therapy and cardiology.Key Takeaways:LMHRs on a long-term ketogenic diet who show elevated LDL can show robust metabolic healthLDL-C and ApoB were not linked to plaque progression in LMHRsExisting plaque did predict future plaque accumulation in LMHRsIndividualized approaches to cardiovascular risk assessment are crucial to serve this group better.

This interview with JACC: Associate Editor Neha J. Pagidipati, MD, FACC, and author Kausik Ray, MD, FACC, reviews Dr. Ray's phase one study on solbinsiran, an siRNA therapy targeting ANGPTL3 to reduce triglycerides and cardiovascular risk. Dr. Ray explains the study's findings, including significant reductions in triglycerides, ApoB, and LDL, with a favorable safety profile. The conversation also touches on the broader landscape of ANGPTL3 inhibitors, the implications of HDL reduction, and the anticipation of phase two results to be presented at ACC 2025.

JACC Associate Editor Khurram Nasir, MBBS, FACC, speaks with author Michael J. Koren, MD, FACC, on his Featured Clinical Research study published in JACC and presented at ACC.25. This randomized, multicenter, double-blind, placebo-controlled, dose-ranging phase 2 study assessed efficacy, safety, and tolerability of AZD0780, a small molecule PCSK9 inhibitor. The study randomized 428 patients (426 started treatment) with hypercholesterolemia on standard-of-care statin therapy to daily oral administrations of AZD0780 1, 3, 10 or 30 mg, or matching placebo for 12 weeks. AZD0780 significantly reduced LDL-C levels versus placebo at all doses (from 35.3% to 50.7%) and demonstrated a safety and tolerability profile similar to placebo. These findings support further development of AZD0780 as part of a simple, oral regimen for lowering LDL-C beyond that achieved with statin therapy.

Notre émission mensuelle autour du basket français est de retour ! Erwan Abautret, Thomas Dufant et Thomas Larrouquis se retrouvent pour la 6ème émission de #LNBDAZNClub avec @daznfrance

ไลฟ์ #91: ประสิทธิภาพในการเคลียร์ LDL-C ด้วย LDL-Receptor ของมนุษย์ แตกต่างจาสัตว์อื่นอย่างไร มนุษย์เป็ Carnivore จริงหรือ?โดยวิวัฒนาการ มนุษย์เป็นสายพันธุ์ที่ไม่อาจเรียกได้ว่าประสบความสำเร็จที่สุดบนโลกใบนี้เพราะ1. ด้วยจำนวนประชากรราว 8 พันล้านคน เทียบไม่ได้เลยกับประชากรมดที่มีนับร้อยพันล้านตัว2. ถ้าเปรียบเทียบในเชิงไบโอแมสกันแล้ว มีจำนวนวัวมากกว่ามนุษย์ 50%3. ในแง่ของความมีอายุขัยที่ยืนยาว มนุษย์สายพันธุ์โฮโมเซเปียนเพิ่งถือกำเนิดบนโลกราวแสนปี ในขณะที่ Horseshoe Crab Limulus อยู่บนโลกนี้มาแล้ว 150 ล้านปีมีอยู่อย่างเดียวที่มนุษย์ทำได้ดีกว่าสายพันธุ์อื่น คือการมีสมองที่ประเสริฐและขึ้นมาเดินสองขา ทำให้มนุษย์กระจายเผ่าพันธุ์ไปทั่วโลกจาก Arctic Greenland ถึง ทะเลสาปเดดซี เป็นที่มาของคำถามที่ดีเบตกันมานานที่สุดในประวัติศาสตร์มนุษยชาติคือWhat is human nutrition? มนุษย์เป็นสัตว์ที่กินสัตว์อย่างเดียว (Carnivore) หรือกินพืชอย่างเดียว (Herbivore) หรือ กินทั้งพืชและสัตว์ (Omnivore)ในไลฟ์ #91 พี่ปุ๋ม จะนำหลักฐานงานวิจัยและจากหนังสือด้านวิวัฒนาการที่น่าสนใจมาเล่าให้น้องๆฟัง แต่งานวิจัย 2 ฉบับที่นำมาแสดง จะมุ่งเน้นที่เรื่องประสิทธิภาพการเคลียร์ LDL-C ออกจากกระแสเลือดกลับตับด้วย LDL-Receptor ในสัตว์ต่างสายพันธุ์รวมถึงมนุษย์ เพื่อสนับสนุนว่าโดยวิวัฒนาการแล้ว มนุษย์ไม่ได้มีธรรมชาติเป็นสัตว์ที่กินเนื้อสัตว์แต่เพียงอย่างเดียว (Carnivore) หรือกินพืชแต่เพียงอย่างเดียว (Herbivore) แต่เราเป็นสายพันธุ์ที่เรียกว่า Opportunistic Omnivoresเชิญพบกับไลฟ์#91 ได้เลยค่ะสารบัญ0:00:00 Introduction0:05:00 Hot News0:15:07 สรปงานวิจัย Role of liver in the maintenance of cholesterol and low density lipoproteinhomeostasis in different animal species, including humans.01:05:55 หลักฐานจากหนังสือ 2 เล่มว่า มนุษย์ไม่ใช่ Carnivore, Herbivoreแต่คือ Opportunistic Omnivore01:14:28 บทสรุป

ไลฟ์ #90: หลักฐานทางคลินิคและพยาธิวิทยา ที่สนับสนุน “The zero-LDL Hypothesis”วันจันทร์ 24 ก.พ. 2568เวลา 20.00 น.✅ จากหลักฐาน A consensus statement from the European Atherosclerosis Society Consensus Panel“Low-density Lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic. Epidemiologic, and clinical studies.ตีพิมพ์ใน European Heart Journal 24 April, 2017 ซึ่งรวบรวมการติดตามคนไข้ไป 20 million person years พบความสัมพันธ์เชิงเส้นตรงระหว่างระดับ LDL-Cholesterol กับ ความเสี่ยงของโรคหลอดเลือดหัวใจ ยิ่งลดระดับ LDL-Cholesterol ได้ต่ำเท่าไหร่ ความเสี่ยงของโรคหลอดเลือดหัวใจก็ลดลงเท่านั้น✅ ถึงแม้ว่าจะมีหลักฐานทางคลินิกที่สนับสนุนผลลัพธ์ของการลดระดับ LDL-C ในการป้องกันการเกิดโรคหลอดเลือดหัวใจมากแค่ไหนก็ตาม มันก็ยังคงน่าสนใจเป็นอย่างยิ่งที่จะศึกษาว่า การลดระดับ LDL-C ให้ต่ำอย่างยิ่งยวด มีผลกระทบต่อภาวะธำรงดุลของไขมันในเลือด (Lipid Homeostasis) หรือไม่

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals. Each week, we highlight 5 key developments or headlines from healthcare that you need to know—whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories included the US Food and Drug Administration's (FDA) acceptance of a Biologics License Application (BLA) for a cholesterol-lowering drug, long-term data on a dermatologic treatment for hidradenitis suppurativa, an expanded dosing label for a blinding eye disease treatment, and more! With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here's your quick dive into the top stories for the week of February 09, 2025—let's jump in! Interested in oncology news? Check out The OncFive, from our sister publication OncLive. Top News for Healthcare Providers from the Week of 02/09 1. FDA Accepts Lerodalcibep BLA for LDL-C Reduction in High-Risk Patients The FDA accepted the BLA for lerodalcibep, targeting reductions in low-density lipoprotein cholesterol (LDL-C) levels in patients with or at high risk for atherosclerotic cardiovascular disease (ASCVD) and primary hyperlipidemia. The agency set a Prescription Drug User Fee Act (PDUFA) action date of December 12, 2025, and announced no plans to hold an advisory committee meeting. 2. Travere Therapeutics Plans FSGS Submission for Sparsentan Travere Therapeutics announced its intent to submit a supplemental New Drug Application (sNDA) for sparsentan (Filspari) with the FDA for the treatment of focal segmental glomerulosclerosis (FSGS) at the end of Q1. The announcement arrived soon after the completion of a Type C meeting with the FDA, with the sNDA based on existing data from the Phase 3 DUPLEX and Phase 2 DUET studies. 3. Bimekizumab Long-Term Hidradenitis Suppurativa Data Support Efficacy, Safety Profile Bimekizumab (Bimzelx) was associated with sustained disease control for up to 2 years in patients with hidradenitis suppurativa (HS), according to presentation of long-term data from the BE HEARD trials. Presented at the 14th Conference of the European Hidradenitis Suppurativa Foundation (EHSF), bimekizumab reduced the symptoms of HS, achieved a low rate of flares, and improved health-related quality of life. 4. Rosnilimab Demonstrates Historic Responses for Rheumatoid Arthritis Rosnilimab achieved historic American College of Rheumatology (ACR) and clinical disease activity index (CDAI) low disease activity (LDA) responses in patients with rheumatoid arthritis (RA), according to new Phase 2b findings. A depleter and agonist of PD-1+ T cells, rosnilimab was evaluated in the global 424-patient RENOIR trial for efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with moderate-to-severe RA on background conventional disease-modifying antirheumatic drugs (cDMARDs). 5. FDA Expands Dosing Label for Avacincaptad Pegol for Geographic Atrophy The FDA approved an expanded label for avacincaptad pegol intravitreal solution (IZERVAY) for geographic atrophy (GA), extending the approved dosing beyond 12 months. Announced by Astellas Pharma, the decision comes after the company resubmitted its supplemental New Drug Application (nDA) in December 2024, based on feedback received from the FDA. The company received a Complete Response Letter (CRL) the month prior. See you next week! Editor's note: this was created with the assistance of AI tools. 

Comment une aréna qui souffle sa première bougie est-elle déjà devenue un lieu incontournable pour les plus grandes tournées internationales ? C'est l'une des questions au cœur de cet épisode de Sold Out, enregistré à la LDLC Arena, à Lyon-Décines.Principalement destinée aux spectacles, cette aréna accueille également des événements sportifs, notamment les matchs de basket de l'ASVEL. En compagnie de Xavier Pierrot, directeur général délégué de la LDLC Arena, nous explorons les coulisses de cette infrastructure impressionnante pour comprendre les défis et les opportunités qui l'attendent.Xavier Pierrot est une figure bien connue du monde du sport et du spectacle. Il a débuté sa carrière à la billetterie de l'Olympique Lyonnais avant de gravir les échelons pour devenir Stadium Manager du Groupama Stadium. Aujourd'hui, il est à la tête de la LDLC Arena, un projet qu'il a vu naître et se développer sous l'impulsion de Jean-Michel Aulas. Son expérience et sa passion pour le sport et la culture lui permettent désormais de diriger avec succès l'une des arénas les plus modernes de France.Dans cet épisode, nous revenons sur la genèse de la LDLC Arena, sa conception, et son rôle dans le paysage culturel lyonnais. Nous discutons des défis liés à la gestion d'une aréna moderne, de l'importance de l'acoustique, et de l'accueil du public. Xavier nous parle également des synergies entre le sport et la musique, et de l'avenir de la LDLC Arena dans un marché en constante évolution. Une plongée passionnante au cœur des grandes arénas, avec un regard optimiste sur leur capacité à s'adapter et à innover !Sold Out, le podcast pour se glisser dans les coulisses du spectacle vivant.Avec le soutien de DELIGHT.Production : Big Red Machine / Réalisation : Marc H'LIMI / Interview et programmation : Marc GONNET / Communication & image : Emilie BARDALOUHébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

In this podcast, expert clinicians will review the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in reducing low-density lipoprotein cholesterol (LDL-C) and reducing cardiovascular risk. https://healio.com/cme/mededtalks/cardiology/20250102/4-lipid-legends-with-your-host-dr-ronald-codario-featuring-dr-peter-toth-pcsk9-inhibition

Host: Keith C. Ferdinand, MD, FACC, FAHA , FASPC, FNLA, FPCNA A concerning number of patients with atherosclerotic cardiovascular disease (ASCVD) reached suboptimal LDL-C levels between 2021 and 2022. Even with new strategies that can help lower LDL-C, an analysis of over 3 million ASCVD patients in the Family Heart Database shows that these treatments are not being properly utilized. Join Dr. Keith C. Ferdinand as he delves into an analysis of management trends among these patients, which he presented at the 2024 Family Heart Foundation Global Summit. Dr. Ferdinand is a Professor of Medicine and the Gerald S. Berenson Endowed Chair in Preventative Cardiology at the Tulane University School of Medicine in New Orleans, Louisiana.

People often use the slogan « Everything in Moderation » to either justify unhealthy habits, or to fear monger others. One of my patients was scared of the radiation from a mammogram, while walking around with an LDL-C of 5.2.She refused breast cancer screening when 1/8 women will get diagnosed and also minimized her very high blood cholesterol levels, unknowingly living with a very high risk of cardiovascular disease, our world's top killer.While the scientific literature is quite clear, people online are confused.Go check out my website for tons of free resources on how to transition towards a healthier diet and lifestyle.You can download my free plant-based recipes eBook and a ton of other free resources by visiting the Digital Downloads tab of my website at https://www.plantbaseddrjules.com/shopDon't forget to check out my blog at https://www.plantbaseddrjules.com/blog You can also watch my educational videos on YouTube at https://www.youtube.com/channel/UCMpkQRXb7G-StAotV0dmahQCheck out my upcoming live events and free eCourse, where you'll learn more about how to create delicious plant-based recipes: https://www.plantbaseddrjules.com/Go follow me on social media by visiting my Facebook page and Instagram accountshttps://www.facebook.com/plantbaseddrjuleshttps://www.instagram.com/plantbased_dr_jules/Last but not least, the best way to show your support and to help me spread my message is to subscribe to my podcast and to leave a 5 star review on Apple and Spotify!Thanks so much!Peace, love, plants!Dr. Jules

In this episode of the JACC: Asia podcast, Editor-in-Chief Jian'an Wang examines a study which explores the genetic links between lipid levels and type 2 diabetes risk in the Chinese population, using data from the Quinson community cohort. The findings suggest that lower genetic risk scores for LDL-C and triglycerides are associated with a higher risk of diabetes, highlighting the need for personalized lipid management strategies, especially in light of the potential risks of long-term APOC inhibitor use.

In this podcast, expert clinicians will discuss the latest recommendations to assess cardiovascular risk, residual risk, and low-density lipoprotein cholesterol (LDL-C) goals for therapy.  https://healio.com/cme/mededtalks/cardiology/20241028/1-lipid-legends-with-your-host-dr-ronald-codario

LDLC généralise ce qui n'était qu'une opération commerciale temporaire, pendant un mois, et propose désormais cinq ans de garantie sur iPhone et Mac soit trois ans de plus que les deux années légales au titre de la législation française et européenne. Un sacré argument commercial mais qui ne vaut pas Apple Care + pour autant, ni une véritable assurance tranquilité. Extrait de l'épisode 203 d'iWeek (la semaine Apple).Soutenez-nous en rejoignant la communauté iWeek sur Patreon sur Patreon.com/iweek et profitez du bonus hebdo exclusif ainsi que de la possibilité désormais, le 1er mardi de chaque mois, d'intervenir en direct dans l'émission, en visio, au même titre que nos invités (réservée à nos soutiens Patreon via un lien spécifique).Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Elevated LDL-C is directly associated with the development of ASCVD. Learn about current treatments, barriers in applying guideline-directed therapies, strategies for prioritizing LDL-C in clinical practice, combatting misinformation, and utilizing shared decision-making from guests Kim Prado, DNP, AGPCNP-BC, and Binu Koirala, PhD, MGS, RN, FAAN, FPCNA.2018 Guideline for the Management of Blood Cholesterol: https://www.ahajournals.org/doi/10.1161/cir.0000000000000625 2022 ACC Expert Consensus Decision Pathway on Role of Nonstatin Therapies for LDL-C Lowering in the Management of ASCVD Risk: https://www.jacc.org/doi/10.1016/j.jacc.2022.07.006Evolving Management of LDL-C: https://www.ahajournals.org/doi/10.1161/JAHA.122.028892 Shared Decision-Making and Cardiovascular Health: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001162 JUPITER Trial: https://www.ahajournals.org/doi/full/10.1161/CIRCOUTCOMES.109.868299 ASTEROID Trial: https://jamanetwork.com/journals/jama/fullarticle/202629 See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

CardioNerds Dan Ambinder and Dr. Devesh Rai join cardiology fellows and National Lipid Association lipid scholars Dr. Jelani Grant from Johns Hopkins University and Dr. Alexander Razavi from Emory University. They discuss a case involving a patient with familial hypercholesterolemia. Dr. Archna Bajaj from University of Pennsylvania provides expert commentary. Drs. Jelani Grant and Alexander Razavi drafted notes. CardioNerds Intern Pacey Wetstein engineered episode audio. This episode is part of a case reports series developed in collaboration with the National Lipid Association and their Lipid Scholarship Program, with mentorship from Dr. Daniel Soffer and Dr. Eugenia Gianos. A classic finding in patients with familial hypercholesterolemia is the presence of markedly elevated levels of total and low-density lipoprotein cholesterol (LDL-C) with an LDL-C concentration of 190 mg/dL or greater. However, severe hypercholesterolemia is not inevitably present, and many patients who carry this diagnosis may have lower LDL-C levels. This case history describes a young woman whose mother and brother met clinical and genetic criteria for heterozygous familial hypercholesterolemia but who had only a mild elevation in LDL-C, falling to 130 mg/dL after dietary intervention. Despite this finding, genetic testing revealed the presence of the same genetic variants as were noted in her mother and brother. In addition, a second genetic variant predisposing them to cholesterol gallstone formation was identified in all three family members. If genetic testing had not been performed, the diagnosis may have been missed or delayed, resulting in an increased risk for vascular complications associated with familial hypercholesterolemia. This case supports the value of genetic testing of family members of those with familial hypercholesterolemia, even when LDL-C levels are not severely elevated. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls - Exposing an Unusual Presentation of Familial Hypercholesterolemia – National Lipid Association Familial hypercholesterolemia (FH) is among the most common autosomal co-dominant genetic conditions (approximately 1:200 to 1:300 for HeFH, 1:160,000 to 1:300,000 for HoFH). Genetic testing has a role for all first-degree relatives when a family history of FH is strongly suggestive, regardless of LDL-C level. Heterogeneity in ASCVD risk among individuals with FH is derived from background polygenic risk, clinical risk factors (e.g., timing of lipid-lowering initiation and adjacent risk factors), as well as subclinical atherosclerosis burden. In clinical or genetically confirmed FH, an LDL-C goal of 55 mg/dL is recommended. Beyond statins, FDA-approved non-statin therapies for FH include ezetimibe, PCSK9 mAb, bempedoic acid, inclisiran, evolocumab (only HoFH), lomitapide (only HoFH), and LDL apheresis. Notes - Exposing an Unusual Presentation of Familial Hypercholesterolemia – National Lipid Association What are the diagnostic criteria for FH? Dutch Lipid Clinic Network1 Variables: family history, clinical history, physical exam, LDL-C level, DNA (LDLR, APOB, PCSK9) Simon-Broome1 Variables: total or LDL-C, physical exam, DNA (LDLR, APOB, PCSK9), family history Emphasis on clinical history and physical exam reduces sensitivity U.S. Make Early Diagnosis Prevent Early Death (MEDPED) 1 Only one of the three where no genetic testing is required, may work well in cascade screening Variables: age, total cholesterol, family relative (and degree) with FH Definite, probable, possible, unlikely Emphasis on clinical history and physical exam reduces sensitivity

In this episode of AGE BETTER with Barbara Hannah Grufferman, I dive into a groundbreaking conversation about heart health with one of the world's leading experts on cholesterol and heart disease prevention, Dr. Ann Marie Navar. Dr. Navar is an Associate Professor of Medicine and preventive cardiologist at the University of Texas Southwestern Medical Center, with a research focus on preventing heart disease through cholesterol management. She also serves on the Executive Committee of the American Society of Preventive Cardiology.    KEY TAKEAWAYS:    Understanding ApoB: Dr. Navar explains what ApoB is and why it's a more accurate marker for assessing heart disease risk than traditional cholesterol measurements like LDL-C.    Why ApoB Testing Matters: Learn why measuring ApoB can provide a clearer picture of your heart disease risk, especially if you have metabolic risk factors like obesity, diabetes, or high triglycerides, or even if you appear metabolically healthy.    Current Guidelines and Future Recommendations: Dr. Navar discusses the limitations of the current guidelines that focus primarily on LDL-C and the need to revise these guidelines to include routine ApoB testing for a more comprehensive assessment of heart health.    The Role of Coronary Artery Calcium Score: Discover the importance of the coronary artery calcium score test in evaluating plaque buildup in the arteries and how it can complement ApoB testing for a more thorough evaluation of cardiovascular risk.    Join us for this essential discussion to learn how to take proactive steps in managing your heart health with the latest insights from cutting-edge research.    KEY LINKS:  Learn more about Dr. Ann Marie Navar here.   Read more about Dr. Navar's research on ApoB here.    Get more insights in the Coronary Artery Calcium Score Test here.   More information about lipoprotein (a) here.     Don't forget to subscribe to AGE BETTER with Barbara Hannah Grufferman for more expert advice on how to age better!  Learn more about your ad choices. Visit megaphone.fm/adchoices

The Massive National Public Data Breach; FlightAware Breach; Other HIBP Breaches: LuLu, Shadow, LDLC, Chris Leong; Sponsored by SentinelOne https://www.troyhunt.com/weekly-update-413/See omnystudio.com/listener for privacy information.

A new study published in the Journal of the American Heart Association explores the effects of extra virgin olive oil (EVOO) on cholesterol and heart health. Researchers found that both high and low usage of EVOO in the diet were linked to reductions in LDL-C, the "bad" cholesterol associated with heart disease. But during a 4-week carryover period, an interesting twist was revealed. Listen in this week as Dee discusses the results of the study, it's pros and cons, and how it could impact your health.Reference: Krenek, A. M., Mathews, A., Guo, J., Courville, A. B., Pepine, C. J., Chung, S. T., & Aggarwal, M. (2024). Recipe for heart health: A randomized crossover trial on cardiometabolic effects of extra virgin olive oil within a whole‐food plant‐based vegan diet. Journal of the American Heart Association, 13(15), e035034. https://www.ahajournals.org/doi/10.1161/JAHA.124.035034

"Depuis que je suis en maternelle, je veux être entrepreneur."Alors qu'il n'est qu'en cinquième, loin de se douter de son futur succès, Laurent écrit ces mots dans une rédaction. Quelques années plus tard, en 1996, tandis qu'il est encore étudiant, son rêve se réalise.Peu à peu, son quotidien se transforme et le site e-commerce qu'il est en train de créer pour apprendre devient une opportunité à saisir. À l'époque, c'est l'apparition des premiers modems 56k, l'adsl n'est pas encore arrivée, le développement web démarre à peine. De fil en aiguille, la demande s'accélère et Laurent s'entoure. Ses premiers employés sont des passionnés, comme lui, ainsi que des membres de sa famille.Ensemble, ils créent une enseigne de confiance que la première boutique, en 1998, vient consolider. Depuis, ils entrent en bourse et se développent au fil des années. Pourtant, si aujourd'hui LDLC c'est : Le n°1 du high-tech et du matériel informatique en France 1150 collaborateurs 600 Millions de CA 28+ années d'expérience dont 25 années rentables Le chemin pour y parvenir n'a pas été de tout repos et, des galères, Laurent en a connu. Peuvent en témoigner les années 2005 et 2008 où, malgré de nombreux efforts, tout a bien failli s'arrêter... Intrigué(e) ? On ne vous en dit pas plus et on vous laisse découvrir plus en détails et sans plus attendre l'histoire et les galères de LDLC, dès maintenant sur le podcast La Galère. Au programme : Les débuts d'un passionné : apprendre avant de vendre Travailler en famille (et rester soudés) Mettre l'humain au coeur de son business Manquer 35 000 commandes, et se racheter Désamorcer les tensions lors d'une acquisition Bonne écoute ! 

HEALTH NEWS   ·         Fatty liver, cardiovascular function improved in MASLD patients given CoQ10 ·         Mediterranean Diet Improves Heart Health For Kids Too, Study Reveals ·         Vitamin D and Curcumin Piperine Offer New Hope for Lupus Patients ·         Simply Looking At Greenery Can Boost Mental Health – New Research ·         Lifelong low LDL-C levels key to preventing cardiovascular disease ·         The Average American Woman Now Weighs As Much As 1960s Man  

許多人對癌症聞之色變，事實上心血管疾病的死亡總人數，已經超過所有癌症的死亡人數，且差距持續擴大中。根據死亡時鐘的最新數據，每7分34秒即有1人因三高慢性疾病而死亡，比癌症速度更快，是很大的警訊。 台北榮總心臟衰竭中心主任江晨恩認為，其實心血管疾病的預防效果遠比癌症預防更顯著，他提出「護心八要點」，只要切實奉行，即可大幅減少死亡機率。 被醫學界尊稱為「江神」及「老師中的老師」的江晨恩，幾年前發現自己的動脈有斑塊堆積，隨即開啟了他的「心血管逆齡大作戰」。他成功將壞膽固醇數值降到25，這如同新生兒一般低的數字，真的可以讓血管逆齡、遠離心血管病變嗎？此外，他在半年內減重5公斤，靠的是一支特斯拉執行長馬斯克都在打的「瘦瘦針」，不僅宣稱可瘦身，還能預防心肌梗塞、中風、腎病變與心臟衰竭。這聽來神奇的針劑，適合一般人施打嗎？有沒有副作用？ ✅本集節目重點 1. 擺脫心血管疾病威脅，「護心8要點」怎麼做？ 2. 努力降壞膽固醇，真能遠離心臟疾病？ 3. 明星、企業家都在打，賣到全球大缺貨的「瘦瘦針」，安全嗎？ 4. 藥都是毒，真的嗎？ 5. 保護心血管，「這種」飲食方式效果最好！ 主持人：《50+》總顧問 周慧婷 來賓：台北榮總心臟衰竭中心主任 江晨恩 製作團隊：賴慧勳、胡念慈 《50+學院》熟齡踢踏舞入門班： https://www.fiftyplus.com.tw/activity/1217 《50+學院》熟齡踢踏舞初階班：https://www.fiftyplus.com.tw/activity/1216

Dave Feldman is the founder of the Citizen Science Foundation and is known for his research into the ketogenic diet. Dave is a software engineer by training who embraced a ketogenic diet to avoid his progression toward type 2 diabetes. he joins us on this episode of STEM-Talk to share that journey. After undertaking the high-fat/low-carbohydrate diet, Dave' LDL cholesterol spiked. Dave used his training as an engineer to start learning everything he could about cholesterol and lipids. What he learned led him to create the website Cholesterol Code, a research hub for information and emerging data on cholesterol, particularly in the context of a low-carbohydrate lifestyle. Dave's Citizen Science Foundation is designed to support projects and research that promote collaborative efforts across multiple disciplines, both in and outside formal scientific institutions. Show notes: [00:02:53] Dawn opens the interview asking Dave what he was like as a kid. [00:03:44] Dawn mentions that Dave divided his time as a child between Denver and Wichita due to his parents' divorce and asks Dave what the best part of his childhood was. [00:04:28] Ken mentions that Dave has described both his parents as graphic artists and Bohemian, “hippie spirit” types. Ken asks what he learned from them that fueled his interests and goals. [00:05:46] Ken asks about Dave's first computer, which was a Commodore 64, as well as his early experience with computers. [00:08:50] Dawn mentions that Dave's interest in computers came in a time before the internet and asks what he learned about computing in those days. [00:10:51] Dawn explains that since Dave grew up in the 1980s, there was not much in the way of computer science curriculum in schools and asks Dave how he supported his interest in programming. [00:12:33] Ken asks Dave about how self-directed learning has been a theme throughout his whole life. [00:14:35] Dawn asks Dave about his childhood hobbies, including running and competitive storytelling. [00:17:01] Ken asks how Dave's experiences in forensic debate in high school helped his career later in life. [00:18:56] Dawn mentions that Dave initially attended film school and asks if it is true that Dave's side hustle of doing contract software work overtook his original plan to graduate. [00:20:49] Dawn asks about Dave's experiences working in the game platform development business in Las Vegas, as well as what these experiences taught him. [00:22:23] Ken asks Dave about a “the piece of paper” that Dave says changed his life in 2015. [00:28:58] Ken follows up, asking Dave if he checked his LDL-P or his ApoB at the same time as his cholesterol levels. [00:30:37] Ken mentions that he knows some people that when consuming a ketogenic diet did not see a substantial increase in LDL-C, but did experience a substantial elevation of LDL-P. [00:35:03] Ken pivots to discuss a paper that Dave and others published in Current Developments in Nutrition in 2022 titled: “Elevated LDL Cholesterol with a Carbohydrate-Restricted Diet: Evidence for Lean Mass Hyper-Responder Phenotype.” Ken asks Dave to describe what it means to be a lean mass hyper-responder. [00:40:19] Ken mentions his caution against the term lean mass hyper-responder, as it is unclear what “lean mass” refers to in this case. Ken goes on to say that while the lean mass hyper-responder phenotype can be objectively measured in terms of LDL, HDL and triglyceride levels, the lean mass aspect is often measured in these studies with BMI, which is unable to measure body composition. Ken asks Dave what his thoughts are on this and if he would like the possibility of moving away from BMI and towards DEXA scans. [00:43:37] Ken mentions that Dave's original article describing the lean mass hyper-responder phenotype has received a lot of response from individuals claiming to fall into that category. While it is difficult to get a precise estimate of the popul...

Cholesterol-lowering medications, particularly statins, play a pivotal role in reducing low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) concentrations, which are causal markers in atherosclerosis development. The efficacy of these medications is well-documented, with numerous clinical trials demonstrating substantial benefits in reducing cardiovascular events and improving overall mortality rates. Despite the robust evidence supporting the benefits of cholesterol-lowering medications, there are various misconceptions and misunderstandings regarding their use. One common myth is that these drugs are unnecessary for those without overt cardiovascular symptoms, ignoring the preventative benefits for at-risk individuals. Concerns about side effects, such as muscle pain, liver damage, and cognitive impairment, are often exaggerated. While side effects are possible, they are typically mild and manageable. Regular monitoring and adjustments by healthcare providers can help mitigate any adverse effects, ensuring that the benefits of reducing LDL-C and apoB far outweigh the risks. In this episode, preventative cardiologist Dr. Paddy Barrett discusses the different types of lipid-lowering medications, their mechanisms of action, the side effects that may occur, and the misconceptions about the drugs that are unfortunately widespread. Timestamps: 00:14 Introduction 03:26 Dr. Barrett's Background 04:50 What is “Lipid Lowering”? 05:30 Overview of Lipids and Atherosclerosis 09:58 Setting Targets for Lipid Levels 15:52 Medications for Lowering LDL and ApoB 20:12 Statins: Types, Effects, and Side Effects 35:38 Addressing Concerns and Misconceptions 42:47 Future of Lipid Lowering Therapies Links: Go to episode page Subscribe to Sigma Nutrition PREMIUM drpaddybarrett.com Dr. Barrett's Substack Book: Heart. An Owner's Guide Receive our free weekly email: the Sigma Synopsis

Are you up to date on low-density lipoprotein cholesterol (LDL-C)–lowering therapy in high-risk patients? Credit available for this activity expires: 06/06/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000828?ecd=bdc_podcast_libsyn_mscpedu

This case report explores the intricacies of familial hypercholesterolemia (FH), delving into its genetic basis, atherosclerotic cascade, and early-onset cardiovascular complications. It examines established diagnostic criteria and emphasizes personalized management, including statins, novel therapies, and lifestyle modifications. CardioNerds cofounders (Drs. Amit Goyal and Danial Ambinder) join Dr. Irfan Shafi, Dr. Preeya Prakash, and Dr. Rebecca Theisen from the Wayne State University/DMC and Central Michigan University at Campus Martius in Downtown Detroit for some holiday ice-skating! They discuss an interesting pediatric case (see case synopsis below). Dr. Luis C Afonso provides the Expert CardioNerd Perspectives & Review segment for this episode. Audio editing by CardioNerds academy intern, Pace Wetstein. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Synopsis FH, a 9-year-old female with no previous medical history, recently moved back to the US from Iraq. She presented to establish care and discuss new-onset chest pain and dyspnea. A systolic ejection murmur was noted during her initial visit to the pediatrician, prompting cholesterol testing and a cardiology referral. Testing revealed, alarming cholesterol levels (Total Cholesterol: 802 mg/dL, LDL: 731 mg/dL, Triglycerides: 123 mg/dL) prompted concern for cardiac involvement. Due to persistent symptoms, FH was transferred to Children's Hospital of Michigan. Despite normal findings on EKG and chest x-ray, a 2/6 systolic murmur was noted. She was discharged with a cardiology clinic follow-up. However, two days later, FH experienced severe chest pain at rest, sweating, and difficulty breathing. She was transported to Children's Hospital again, and her troponin level measured 3000, and her total cholesterol was 695 mg/dL. An echocardiogram revealed valvar and supravalvar aortic stenosis, necessitating collaboration between Pediatric and Adult cardiology teams. CTA thorax revealed severe supravalvular stenosis, a hypoplastic right coronary artery, and significant coronary artery obstructions. Diagnostic cardiac catheterization confirmed severe aortic stenosis and coronary artery disease, leading to the decision for surgical intervention. FH underwent the Ross operation, left main coronary artery augmentation, and right coronary artery reimplantation. Intraoperatively, atherosclerotic plaques were observed in multiple cardiac structures. FH's recovery was uneventful, discharged on a regimen including Atorvastatin, Ezetimibe, evolocumab, and antiplatelet therapy. Persistent high LDL levels required regular plasmapheresis. Plans for evaluations in Genetics, Lipid Clinic, Endocrine, and Gastroenterology were made, potentially leading to a liver transplant assessment. Given the severity of her condition, a heart/liver transplant might be considered in the future. Conclusion: This case of FH highlights the complex presentation of severe aortic stenosis and coronary artery disease in a pediatric patient. Urgent diagnosis, interdisciplinary collaboration, and aggressive management were crucial. The case underscores the importance of comprehensive care for pediatric patients with rare cardiac conditions, emphasizing collaboration between specialties for optimal outcomes and long-term well-being. Case Media Pearls - Familial Hypercholesterolemia Mutations in LDLR, ApoB, or PCSK9 genes disrupt LDL-C clearance, leading to a cascade of events culminating in accelerated atherosclerosis and early-onset cardiovascular complications (e.g., CAD, aortic stenosis, PAD, stroke). Diagnosis of familial hypercholesterolemia relies on ...

This three part series consists of 3 cases that illustrate important concepts in managing patients with familial hypercholesterolemia, patients with hyperlipidemia and cardiometabolic comorbidities, and patient with South Asian descent with increased risk of ASCVD and a history of percutaneous Intervention. The cases are designed to be quick and offer high-level takeaways and pearls.   In this podcast, experts will discuss the following case: A 62-Year-Old Diabetic Woman with an LDL-C of 53 mg/dL 

A 22-year follow-up study involving 177,000 individuals reveals that low LDL cholesterol is associated with higher cardiovascular-specific mortality. The authors of this study write, "...the lowest risk for long-term mortality appears to exist in the wide LDL-C range of 100–189 mg/dL, which is much higher than current recommendations." Support your Intermittent Fasting lifestyle with the Berberine Fasting Accelerator by MYOXCIENCE: bit.ly/berberine-fasting-accelerator Use code podcast at checkout to save Links to Research & Video: https://bit.ly/4asJ4t3 Key Takeaways:  0:00 Intro 0:04 22 Year Study 0:22 Study Title 0:52 Study Findings  1:52 Probability of survival  2:12 Counterintuitive Findings 3:42 High LDL and odds of death  3:59 U-Shaped Curve 5:50 Metabolic Health 6:34 Study of 177,000 people  8:09 Lowest risk of mortality  9:17 Watch this! 11:01 Lipid paradox

Did you know that greatly reduced low-density lipoprotein (LDL) receptor activity in homozygous familial hypercholesterolemia (HoFH) leads to severely elevated LDL-cholesterol (LDL-C) levels from birth causing very early onset of cardiovascular disease (CVD) events? Credit available for this activity expires: 3/28/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000494?ecd=bdc_podcast_libsyn_mscpedu

Nascentmc.com for medical writing assistance for your company. Visit nascentmc.com/podcast for full show notes Visit learnAMAstyle.com for free downloads regarding editing and the AMA Manual of Style tip sheet.  Nexletol and Nexlizet for LDL Lowering and CV Risk: The FDA approved bempedoic acid (Nexletol) and its combination with ezetimibe (Nexlizet) for reducing cardiovascular risk and treating primary hyperlipidemia. Bempedoic acid inhibits a cholesterol synthesis enzyme, while ezetimibe blocks cholesterol absorption, both lowering LDL-C levels. The approval, for high-risk patients not yet having cardiovascular events, was based on the CLEAR Outcomes trial. Iclusig for ALL: The FDA granted accelerated approval to ponatinib (Iclusig) with chemotherapy for treating previously untreated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Ponatinib, a tyrosine kinase inhibitor, is the first targeted agent for this leukemia type in combination with chemotherapy, based on the PhALLCON trial results. Further confirmatory data may be required to verify its clinical benefit. Elahere for Ovarian Cancer: Mirvetuximab soravtansine-gynx (Elahere) received FDA approval for treating folate receptor alpha-positive, platinum-resistant ovarian cancer, marking it as the first antibody-drug conjugate in the U.S. for this condition. The treatment targets cancer cells by binding to the folate receptor alpha, delivering a cytotoxic agent. Approval was based on the Phase 3 MIRASOL trial. Duvyzat for DMD: The FDA approved givinostat (Duvyzat) for patients 6 years or older with Duchenne muscular dystrophy (DMD), a rare neuromuscular condition. Givinostat is an HDAC inhibitor that mitigates muscle damage and slows disease progression. Approval was based on the EPIDYS trial results, granted to Italfarmaco S.p.A. Spevigo for Psoriasis: Spesolimab-sbzo (Spevigo) received FDA approval for treating generalized pustular psoriasis (GPP) in adults and pediatric patients, expanding its indication from initial approval for GPP flares. As the first targeted therapy for GPP, it acts as an IL-36 receptor antagonist. The expanded approval was based on the Effisayil 2 trial, showing significant reduction in GPP flares. Tryvio for Hypertension: The FDA approved aprocitentan (Tryvio) in combination with other antihypertensive drugs for adults not adequately controlled on other medications, marking it as the first new oral antihypertensive therapy pathway in nearly 40 years. Based on the PRECISION trial, aprocitentan was shown to be effective in patients with resistant hypertension. Opsynvi for PAH: Macitentan and tadalafil (Opsynvi) was approved by the FDA for adults with pulmonary arterial hypertension (PAH) and WHO functional class II-III, as the first once-daily single-tablet combination therapy for PAH. The approval was based on the A DUE study, demonstrating greater reduction in pulmonary vascular resistance compared to monotherapies. Lenmeldy for Juvenile Metachromatic Leukodystrophy: The FDA approved Lenmeldy (atidarsagene autotemcel) gene therapy for children with metachromatic leukodystrophy (MLD), a rare genetic disease affecting the brain and nervous system. The therapy uses the patient's own genetically modified stem cells to produce the missing enzyme. Approval was based on significant improvements in survival, mobility, and cognitive functions observed in clinical trials and an expanded access program.

Ep. #70 Join us in this episode as we delve into the fascinating world of nutrition with Simon, exploring his journey from curiosity to expertise. From the debate between veganism and the carnivore diet to dissecting social media extremes versus scientific thinking, we navigate through topics like Bio Individuality, the Mediterranean diet, Danish Dietary Guidelines, and the American food pyramid.  Uncover the truth about saturated fats, cholesterol, and the impacts on heart health. We'll even touch on the Hadza tribe's lifestyle and diet, questioning ancestral norms and finding a sustainable approach. Whether you're into ketogenic diets, fish consumption, or the nuances of veganism, this episode takes a deep dive into the diverse realms of nutrition, emphasizing the importance of domain-specific experts in shaping a healthy lifestyle. Leave Me a Message - click here! For Mari's Instagram click here! For Pursuit of Wellness Podcast's Instagram click here! For Mari's Newsletter click here! For Simon Hill's Instagram click here! For Simon Hill's Podcast click here! For The Living Proof Challenge click here! Show Links Bite is offering our listeners 20% off your first order. Go to trybite.com/POW or use code POW at checkout to claim this deal. Right now, Chomps is offering our listeners 20% off your first order and free shipping when you go to Chomps.com/POW Today my listeners receive 20% OFF any AquaTru purifier! Just go to AquaTru.com and enter the code “POW” at checkout. Studies and Links From Simon: 1) Saturated fats versus unsaturated fats 2) High saturated fat rich low carb diet in healthy women markedly raises LDL-C and ApoB in just 4 weeks 3) Plant-based dietary patterns typically lower LDL-C by 0.3 mmol/l which equates to about 20% reduction in risk of atherosclerotic CVD 4) The hadza 5) Red meat does increase LDL-C and ApoB 6)Swapping animal protein for plant protein improved LDL-C levels 7) LDL-C is causal in development of atherosclerotic CVD 8) All cells produce their own cholesterol and the brain does not rely on systemic cholesterol 9) Low cholesterol does not negatively affect sex hormones 10) When optimal protein is achieved (1.6g per Kg), there is no difference in strength/hypertrophy between animal and plant protein 11) Total protein and plant protein are associated with reduced mortality. Swapping animal protein for plant protein is associated with reduced mortality 12) Two clinical studies looking at soy foods, or soy isoflavones, fed to men that measured semen parameters and/or sex hormones: https://pubmed.ncbi.nlm.nih.gov/11352776 https://pubmed.ncbi.nlm.nih.gov/19819436/ 13) Meta-analysis of 38 clinical interventions looking at soy foods/isoflavones and sex hormones: 14) Danish dietary guidelines and 3 other evidence-based nutrition guidelines 

Dive into an enthralling new episode at the Kahn Center this week, where Dr. Joel Kahn delves into groundbreaking research on Lipoprotein(a). He reveals that, particle for particle, it's significantly more atherogenic than LDL-cholesterol. However, given the higher prevalence of LDL-C particles, focusing on reducing LDL-C remains crucial. Next, Dr. Kahn explores an intriguing study on using high doses of vitamin K2 and D3 to slow down coronary artery calcification. The episode's highlight is the exciting research on a New Zealand-based product, Calocurb, and its potential to reduce appetite and calorie intake. This discovery is particularly noteworthy as the mechanism mirrors that of injectable drugs like Wegovy and Mounjaro, but Calocurb is available as an affordable oral capsule. Dr. Kahn shares his personal experiences with Calocurb, detailing its impact on his mealtime routines. Plus, listeners can enjoy a special offer – use the discount code 'Joel10' for savings on their purchase. Discover how Calocurb has been effectively integrated into fasting programs, enhancing their success.

Reverse causation and causality can make it look like LDL cholesterol caused increased death rates. Here is a brilliant study that corrected for all covariates and cofounders and found that shows that when you adjust correctly, low LDL-C is actually protective. https://dralo.net/links

Understand the vocabulary of cholesterol so that we are all on the same page and having the same conversation. What's the difference between LDL cholesterol versus LDL particles versus apolipoprotein B (ApoB)? LDL-C, LDL-P, ApoB, Lp(a) https://dralo.net/links

This is a Premium-exclusive episode, so here you'll only hear a preview. In order to listen to the full episode you'll need to subscribe to Sigma Nutrition Premium. About This Episode: It has been clearly demonstrated that elevated LDL-cholesterol (LDL-C), or perhaps more specifically pro-atherogenic lipoproteins, is causal in atherosclerosis development in humans. One crucial concept within this is that the risk relates not only to the magnitude of elevated LDL-C, but the duration of exposure. Thus, the role of LDL-C in driving atherosclerosis is referred to as a “cumulative, integrated exposure over the lifecourse”. But, what exactly does this mean? In this episode, Danny discusses the cumulative exposure model of LDL-C in atherosclerosis, the evidence supporting it, and the implications of this for the “debates” that get raised in relation to LDL-C (or apoB-containing lipoproteins) and heart disease. Links: Subscribe to PREMIUM See more episodes on heart disease and lipids Receive the free Sigma email newsletter

The following question refers to Figures 6-8 from Sections 3.2 of the 2021 ESC CV Prevention Guidelines. The question is asked by student Dr. Hirsh Elhence, answered first by Ohio State University Cardiology Fellow Dr. Alli Bigeh, and then by expert faculty Dr. Eugene Yang.Dr. Yang is Professor of Medicine at the University of Washington where he is also the Medical Director of the Eastside Specialty Center and the co-Director of the Cardiovascular Wellness and Prevention Program. Dr. Yang is former Governor of the ACC Washington Chapter and as well as former Chair of the ACC Prevention of CVD Section.  The CardioNerds Decipher The Guidelines Series for the 2021 ESC CV Prevention Guidelines represents a collaboration with the ACC Prevention of CVD Section, the National Lipid Association, and Preventive Cardiovascular Nurses Association.Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. Question #31 The 2021 ESC CV Prevention guidelines recommend a stepwise approach to risk stratification and treatment options. What is the first step in risk factor treatment regardless of past medical history, risk factors, or established ASCVD?AInitiate statin for goal LDL

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this “Ask Me Anything” (AMA) episode, Peter answers questions related to the leading cause of death in both men and women—atherosclerotic cardiovascular disease (ASCVD). He highlights the most important risk factors for ASCVD, such as apoB, LDL, hyperinsulinemia, and Lp(a), and explains the mechanism by which they confer risk and how these factors are interrelated. Peter also dives deep into the data around apoB to try to answer the question of how much residual risk is conferred for ASCVD through metabolic dysfunction once you correct for apoB. He also looks at the data around lifetime risk reduction of ASCVD in the context of low apoB. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #42 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: A racecar analogy for understanding atherosclerotic cardiovascular disease [2:00]; Defining and differentiating apoB and LDL-C [10:00]; The interrelated nature of insulin levels, apoB, triglycerides, and ASCVD parameters [13:00]; Another way that hyperinsulinemia plays a role in endothelial dysfunction [18:00]; Why Peter uses the oral glucose tolerance test (OGTT) with all patients [20:15]; Is there any evidence that hyperinsulinemia is an independent contributor to ASCVD? [23:00]; Thinking through risk in the context of high-fat diets resulting in improved metabolic metrics but with an elevation of apoB/LDL-C [27:30]; Thinking through risk in the context of low apoB but higher than normal triglyceride levels [32:15]; The importance of lowering apoB for reducing ASCVD risk [38:15]; Data on men and women with familial hypercholesterolemia that demonstrates the direct impact of high apoB and LDL-C on ASCVD risk [47:45]; Importance of starting prevention early, calcium scores, and explaining causality [52:30]; Defining Lp(a), its impact on ASCVD risk, and what you should know if you have high Lp(a) [56:30]; Lp(a) and ethnic differences in risk [1:00:30]; Why someone with elevated Lp(a) should consider being more aggressive with apoB lowering strategies [1:05:00]; Addressing the common feeling of hesitancy to taking a pharmacologic approach to lower ASCVD risk [1:07:15]; Peter's take on the 2022 Formula 1 season and thoughts on 2023 [1:15:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

I've long recommended limiting your saturated fat intake to no more than 10% of your total daily calories. Some people disagree with this, though. In fact, a popular position these days is that saturated fat is a “superfood” and you can eat as much as you want if it's from certain unprocessed foods. Is that true? What does science say? Does saturated fat cause cardiovascular disease? Is saturated fat from unprocessed food like meat and dairy “good” or “bad”? Find out in this podcast. I've written and recorded a lot of evidence-based content over the years on just about everything you can imagine related to building muscle, losing fat, and getting healthy. I've also worked with thousands of men and women of all ages and circumstances and helped them get into the best shape of their lives. That doesn't mean you should blindly swallow everything I say, though, because let's face it—nobody is always right about everything. And especially in fields like diet and exercise, which are constantly evolving thanks to the efforts of honest and hardworking researchers and thought leaders. This is why I'm always happy to hear from people who disagree with me, especially when they have good arguments and evidence to back up their assertions. Sometimes I can't get on board with their positions, but sometimes I end up learning something, and either way, I always appreciate the discussion. That gave me the idea for this series of podcast episodes: publicly addressing things people disagree with me on and sharing my perspective. Think of it like a spicier version of a Q&A. So, here's what I'm doing: Every couple of weeks, I'm asking my Instagram followers what they disagree with me on, and then picking the more common or interesting contentions to address here on the podcast. And in this episode, I'll be tackling the following . . . Saturated fat in unprocessed foods like beef and dairy is healthy. Timestamps: 0:00 - Find the Perfect Strength Training Program for You: www.muscleforlife.show/trainingquiz 4:31 - What are saturated fats? 5:42 - Are saturated fats a cause of cardiovascular disease? 21:14 - Is it dangerous to consume saturated fats? 22:24 - What are your thoughts on LDLC and cardiovascular disease? Mentioned on the Show: Find the Perfect Strength Training Program for You in Just 60 Seconds: http://www.muscleforlife.show/trainingquiz